We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
FDA approved the marketing application of Merck Serono’s Avelumab through accelerated approval on March 23, 2017, which can be said to ignite the medical circle and again draws the public interest in words like “orphan drug” and “rare disease”.